ACLU Files Suit Against Myriad Over BRCA Patents

The ACLU and other plaintiffs allege that Myriad's exclusive rights to diagnostic testing for the BRCA1 and BRCA2 genes "hampers clinical diagnosis and serves as a disincentive for research."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.